Pharmafile Logo

real-time data

Impetus Digital Overview

Virtual engagement experts helping life science companies have ongoing conversations with their customers through our best-in-class online collaboration tools. Best-In-Class Collaboration Technology Impetus Digital provides two turn-key software solutions through...

Impetus Digital

Using Technology-Enabled Human Interactions to Transform the Home into a Site of Care

Sara Aghvami, Director of Best Buy Health at Best Buy Canada, explores the concept of “helpful homes” and the role of digital health in enabling “aging in place.” She also...

Impetus Digital

- PMLiVE

Langland promotes Jake Davis to managing partner

Davis joined Langland in 2020 as business unit director of the agency’s PR and policy division

- PMLiVE

Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer

Keytruda plus Lenvima was previously approved under the FDA’s accelerated approval process

- PMLiVE

J&J, distributors reach $26bn settlement to address the opioid crisis in the US

The proposed agreement would resolve claims of both states and local governments in the US

- PMLiVE

Novartis sees demand returning to pre-COVID-19 levels in Q2 results

Swiss pharma company also provided key updates on a number of drug candidates in its pipeline

- PMLiVE

NHS earmarks £340m for new medicines fund to fast-track ‘innovative’ treatments

The proposed Innovative Medicines Fund is an extension of the existing Cancer Drugs Fund

- PMLiVE

EU approves bluebird bio’s CALD gene therapy Skysona

CALD is a progressive and fatal neurodegenerative disease that overwhelmingly affects males

- PMLiVE

EMA begins rolling review of Sanofi, GSK’s COVID-19 vaccine

Rolling review launched based on preliminary results from lab studies and early clinical studies

- PMLiVE

The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel

Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence

- PMLiVE

AZ licenses pneumonia mAb to Aridis Pharmaceuticals for $11m upfront

The candidate – suvratoxumab – is ready for phase 3 clinical evaluation for the prevention of pneumonia

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links